The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Growth In Market Value Is Anticipated For The Non-Viral Gene Delivery Technologies Market Between 2026 And 2030?
The market for non-viral gene delivery technologies has experienced significant expansion recently. It is projected to expand from $4.57 billion in 2025 to $5.28 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.5%. Historically, this expansion has been driven by factors such as a dependence on viral delivery methods, restricted access to non-viral transfection reagents, a rising focus on gene therapy research, the increased utilization of plasmid DNA and mRNA delivery kits, and the implementation of electroporation along with other physical delivery techniques.
The non-viral gene delivery technologies market is projected to undergo substantial expansion over the upcoming years. This market is set to attain a value of $9.26 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.1%. The anticipated growth during the forecast period stems from factors such as the evolution of advanced lipid and polymer nanoparticles, the proliferation of pre-formulated nanoparticle technologies, increased capital committed to gene editing and RNAi therapeutics, a rising need for personalized gene therapy solutions, and the incorporation of high-throughput and automated delivery platforms. Noteworthy trends anticipated in the same period encompass the broader acceptance of lipid-based and polymer-based non-viral delivery systems, an increase in CRISPR and Cas9 gene editing applications, burgeoning demand for RNAi and DNA vaccine delivery platforms, the broadening scope of ex-vivo and in-vivo gene therapy research, and the creation of cell-specific and targeted gene delivery reagents.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27367&type=smp
Which Major Factors Are Contributing To The Development Of The Non-Viral Gene Delivery Technologies Market?
The increasing demand for personalized medicine is projected to stimulate the growth of the non-viral gene delivery technologies market. Personalized medicine is a medical strategy that customizes prevention, diagnosis, and treatment based on an individual’s unique genetic makeup, lifestyle, and environmental factors. This rising demand for personalized medicine is fueled by advancements in genomic sequencing technologies, which facilitate more accurate diagnoses, targeted therapies, and improved treatment outcomes tailored to specific patients. The heightened emphasis on personalized medicine is consequently boosting the need for non-viral gene delivery technologies, as these methods offer safer and more adaptable ways to deliver therapeutic genes suited to an individual’s genetic profile, without the risks associated with viral vectors. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the Food and Drug Administration (FDA) approved 16 novel personalized therapies for patients with rare diseases in 2023, in contrast to 6 in 2022. Thus, the escalating demand for personalized medicine is driving the expansion of the non-viral gene delivery technologies market.
Which Segment-Based Categories Are Covered In The Non-Viral Gene Delivery Technologies Market?
The non-viral gene delivery technologies market covered in this report is segmented –
1) By Product: Reagents And Kits, Delivery Devices, Pre-Formulated Nanoparticles
2) By Delivery: In-Vitro, In-Vivo, Ex-Vivo
3) By Technology: Electroporation, Lipid-Based Transfection, Polymer-Based Transfection, Physical Methods (Microinjection, Gene Gun), Nanoparticles
4) By Application: Gene Therapy, Deoxyribonucleic Acid (DNA) Vaccines, Ribonucleic Acid Interference (RNAi), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing, Protein Expression
5) By End-Use: Biotechnology And Biopharmaceutical Companies, Research And Academic Institutes, Other End-Uses
Subsegments:
1) By Reagents And Kits: Transfection Reagents, Plasmid Deoxyribonucleic Acid (DNA) Kits, Messenger Ribonucleic Acid (RNA) Delivery Kits, Small Interfering Ribonucleic Acid (RNA) Delivery Kits, Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents, Cell-Specific Delivery Reagents
2) By Delivery Devices: Electroporation Systems, Microinjection Systems, Gene Guns Or Biolistic Delivery Devices, Ultrasound-Mediated Delivery Devices, Hydrodynamic Gene Delivery Systems
3) By Pre-Formulated Nanoparticles: Lipid-Based Nanoparticles, Polymer-Based Nanoparticles, Gold-Based Nanoparticles, Dendrimer-Based Nanoparticles, Carbon Nanotube-Based Nanoparticles, Inorganic Compound-Based Nanoparticles
Which Trends Are Affecting The Non-Viral Gene Delivery Technologies Market Framework?
Leading firms within the non-viral gene delivery market are concentrating on creating sophisticated solutions, including non-viral genetic medicine platforms, to enhance the safety and effectiveness of gene therapies. This platform represents a technology designed to insert therapeutic genes or nucleic acids into cells free from viral vectors, thereby minimizing immune responses and safety issues, and facilitating accurate and regulated gene therapy application across various illnesses. As an illustration, in October 2023, Generation Bio Co., a biotechnology enterprise based in the US specializing in genetic medicine development, introduced immune-quiet DNA (iqDNA). This innovative DNA is an optimized version of their closed-ended DNA (ceDNA), designed to bypass innate immune system detection, demonstrating cytokine levels and tolerability akin to chemically modified mRNA in studies involving mice and non-human primates when administered through their lipid nanoparticle (LNP) system. Owing to iqDNA’s exceptional tolerability, Generation Bio is progressing this as the principal DNA payload in all its initiatives, encompassing its primary hemophilia A program.
Who Are The Major Companies Operating In The Non-Viral Gene Delivery Technologies Market?
Major companies operating in the non-viral gene delivery technologies market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Evonik Industries AG, Moderna Inc., Lonza Group AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.
Access The Complete Non-Viral Gene Delivery Technologies Market Report:
Which Region Contributes The Most To The Non-Viral Gene Delivery Technologies Market?
North America was the largest region in the non-viral gene delivery technologies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral gene delivery technologies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Non-Viral Gene Delivery Technologies Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=27367&type=smp
Browse Through More Reports Similar to the Global Non-Viral Gene Delivery Technologies Market 2026, By The Business Research Company
Low Density Polyethylene Market Report 2026
https://www.thebusinessresearchcompany.com/report/low-density-polyethylene-global-market-report
Polyethylene Pipes Market Report 2026
https://www.thebusinessresearchcompany.com/report/polyethylene-pipes-global-market-report
High Density Polyethylene Market Report 2026
https://www.thebusinessresearchcompany.com/report/high-density-polyethylene-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model